BrBzGCp2 is used as an inhibitor of glyoxalase 1 (GLO1) for research purposes; it exhibits antitumor and neuroprotective activities; it reduces anxiety-like behavior and seizure duration in mice; it alleviates anxiety levels by increasing methylglyoxal (MG) concentration; it restores valproic acid (VPA)-induced inhibition of GABAA receptor activation; it significantly lowers blood pressure and ameliorates endothelial dysfunction in diabetic mice.